Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate von Lone, Zaeem, Benidir, Tarik, Rainey, Magdalena, Nair, Monica, Davicioni, Elai, Gibb, Ewan A., Williamson, Sean, Gupta, Shilpa, Chaim Ornstein, Moshe, Tendulkar, Rahul, Weight, Christopher, Nguyen, Jane K., Klein, Eric A., Mian, Omar Y.

Volltext

Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate... von Ganguly, Shinjini, Lone, Zaeem M., Muskara, Andrew, Imamura, Jarell, Gupta, Shilpa, Ornstein, Moshe Chaim, Sharifi, Nima, Mian, Omar Y.

Volltext

The effect of antibiotic use on immune-checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma von Khan, Mohammad, Radakovich, Nathan, Rini, Brian I., Mian, Omar Y., Ornstein, Moshe Chaim, Gupta, Shilpa

Volltext

Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis von Dhillon, Puneet, Ornstein, Moshe Chaim, Gupta, Shilpa, Nizam, Amanda, Gilligan, Timothy D., Martin, Allison, Bonham, Amanda, Maroli, Kimberly, Wee, Christopher Eing

Volltext

Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial von Hakimi, Kevin, Campbell, Steven, Nguyen, Mimi, Rathi, Nityam, Wang, Luke, Rini, Brian I., Ornstein, Moshe Chaim, McKay, Rana R., Derweesh, Ithaar H

Volltext

Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-r... von Nizam, Amanda, Sheng, Iris Yeong- Fung, Allman, Kimberly D., Martin, Allison, Gilligan, Timothy D., Gupta, Shilpa, Ornstein, Moshe Chaim

Volltext

Impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors in metastatic urothelial carcinoma von Dawsey, Scott, Khan, Mohammad Siddique, Radakovich, Nathan, Wei, Wei, Mian, Omar Y., Ornstein, Moshe Chaim, Gilligan, Timothy D., Gupta, Shilpa

Volltext

The effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitor (ICI) efficacy in patients with metastatic urothelial carcinoma (mUC) in real-world setting von Gupta, Shilpa, Khan, Mohammad Siddique, Radakovich, Nathan, Wei, Wei, Ornstein, Moshe Chaim, Gilligan, Timothy D., Mian, Omar Y., Dawsey, Scott

Volltext

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting von Pramod, Nikhil, Makarov, Vladimir, Dawsey, Scott, Pavicic, Paul G., Patgunarajah, Ubenthira, Nair, Monica, Ornstein, Moshe Chaim, Gilligan, Timothy D., Wee, Christopher Eing, Nizam, Amanda, Mian, Omar Y., Nguyen, Jane, Diaz-Montero, C. Marcela, Gupta, Shilpa

Volltext

Initial screening efforts for the OPTIC RCC trial von Haake, Scott Mattox, Beckermann, Katy, Chen, Yu-Wei, Reddy, Anupama, Mar, Nataliya, Ornstein, Moshe Chaim, Barata, Pedro C., Zhang, Tian, Pal, Sumanta Kumar, Rathmell, W. Kimryn, Rini, Brian I.

Volltext

Topological heterogeneity of genomic and immunologic effects from combination immunotherapy treatment in the neoadjuvant setting for renal cell carcinoma (RCC) von Alban, Tyler, Singh, Salendra, Pavicic, Paul G., Rayman, Patricia A., Bangalore, Prerana Parthasarathy, Rupani, Amit, Makarov, Vladimir, Przybycin, Christopher, Ko, Jennifer S., Krishnamurthi, Venkatesh, Campbell, Steven, Chan, Timothy An-thy, Rini, Brian I., Diaz-Montero, C. Marcela, Ornstein, Moshe Chaim

Volltext

The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting von Patgunarajah, Ubenthira, Dawsey, Scott, Pramod, Nikhil, Maroli, Kimberly, Ornstein, Moshe Chaim, Wee, Christopher Eing, Gilligan, Timothy D., Martin, Allison, Nizam, Amanda, Mian, Omar Y., Wei, Wei, Diaz-Montero, C. Marcela, Pavicic, Paul G., Nguyen, Jane, Gupta, Shilpa

Volltext

The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) von McKay, Rana R., Armstrong, Andrew J., Emamekhoo, Hamid, Gourdin, Theodore Stewart, Heath, Elisabeth I., Hussain, Arif, Ornstein, Moshe Chaim, Sharifi, Nima, Viscuse, Paul Vincent, Yan, Ying, Royal, Mike A.

Volltext

Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) von Pramod, Nikhil, Dawsey, Scott, Pavicic, Paul G., Lodha, Roshan, Patgunarajah, Ubenthira, Nair, Monica, Ornstein, Moshe Chaim, Gilligan, Timothy D., Wee, Christopher Eing, Mian, Omar Y., Nizam, Amanda, Nguyen, Jane, Diaz-Montero, C. Marcela, Gupta, Shilpa

Volltext

A single institution experience of multimodality radiation therapy for muscle-invasive bladder cancer von Nair, Monica, Scarborough, Jessica, Gupta, Shilpa, Gilligan, Timothy D., Nizam, Amanda, Ornstein, Moshe Chaim, Echle, Jessica, Ciezki, Jay P., Stephans, Kevin L., Tendulkar, Rahul D., Scott, Jacob, Mian, Omar Y.

Volltext

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) von Shah, Neil J., Campbell, Matthew T, Mao, Shifeng S., Ornstein, Moshe Chaim, Haas, Naomi B., Gao, Xin, Hammers, Hans J., Keshava-Prasad, Holavanahalli, Yan, Hongxia, Esquibel, Vanessa, Geller, Robert B., Beckermann, Katy

Volltext

Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo) von George, Laeth, Wei, Wei, Diaz-Montero, C. Marcela, Martin, Allison, Vyas, Neil, Basu, Arnab, Beckermann, Katy, Nizam, Amanda, Wee, Christopher Eing, Gilligan, Timothy D., Gupta, Shilpa, Rini, Brian I., Ornstein, Moshe Chaim

Volltext

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical tr... von Runcie, Karie, Ornstein, Moshe Chaim, Saraiya, Biren, Krishnamurthi, Venkatesh, Lee, Byron H, Anderson, Christopher B., DeCastro, Guarionex Joel, McKiernan, James M., Dallos, Matthew, Mayer, Tina M., Marron, Melanie, Kulik, Alexandria, Singer, Eric A., Stein, Mark N.

Volltext

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC) von Stahlfeld, Charlotte, Emamekhoo, Hamid, Kaufmann, Katherine, Grivas, Petros, Ornstein, Moshe Chaim, Sheng, Iris Yeong- Fung, Burkey, Caroline, Sperger, Jamie, Bade, Rory M., Schehr, Jennifer L., Taylor, Amy K, Shi, Yue, Zhao, Shuang, Lang, Joshua Michael

Volltext

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC) von Chen, Yu-Wei, Beckermann, Katy, Haake, Scott Mattox, Reddy, Anupama, Shyr, Yu, Atkins, Michael B., Mar, Nataliya, Ornstein, Moshe Chaim, Pal, Sumanta Monty, Zhang, Tian, Rathmell, Wendy Kimryn, Rini, Brian I.

Volltext